In recent years, mountains of institutional capital have flowed into hundreds of biotech start-ups and so many of them have gone public that it's impossible for anyone with a day job to keep track of them all.
I'll let you in on a little secret. Those of us paid to know things about the biopharmaceutical industry can't keep up with all the new players that reach the Nasdaq exchange, either.
If trying to stay on top of all the new biotech stocks that you could buy has you feeling overwhelmed, relax. Most of them aren't worth the effort. These three stand out as some of the only ones that continued to climb after the buzz around their initial public offerings faded away. Here's why.